ASPET

SEPTEMBER 15, 2023

Mirikizumab effectively inhibits the interaction of IL-23 with its receptor, and potently blocks IL-23-induced IL-17 production in cell-based assays while preserving the function of IL-12. In both local and systemic in vivo mouse models, mirikizumab blocked IL-23-induced keratin mRNA or IL-17 production, respectively.

Cell Based Assays 100

Cell Based Assays Clinical Trials Disease Production 100

Alta Sciences

SEPTEMBER 27, 2024

Featuring two scenarios that explore the complexities of bioanalysis for immunomodulators, The Altascientist offers practical considerations for ensuring accurate bioanalysis, as well as pharmacokinetic, pharmacodynamic , and safety data in clinical trials.

Clinical Trials 52

Clinical Trials Trials Pharmacokinetics Small Molecule 52

The ChEMBL-og

APRIL 16, 2024

The data in MOLECULE_DICTIONARY.MAX_PHASE now includes consideration of: EMA approved drugs (max_phase=4 for human drugs), USAN clinical candidate drugs (assigned as max_phase = 1 based on USAN guidance that states “Firms usually apply for a USAN when the investigational therapy is in Phase I or Phase II trials”.

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Compound Screening 108

Drug Target Review

JULY 6, 2023

1 Ethical concerns surrounding the use of animal studies is increasing, especially considering 90 percent of drug candidates fail in clinical trials. 2 Therefore, the scientific community is researching and developing efficient ways to test compounds without the use of animals, to avoid unsuccessful outcomes in clinical trials.

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

PerkinElmer

AUGUST 13, 2020

Of these 10,000 compounds, some were drugs already approved for other uses; others were drug candidates being used in clinical trials. Following the high-throughput screening were cell-based assays, which demonstrated that the identified leads had strong anti-viral action.

Virus 52

Virus Cell Based Assays FDA Approval Clinical Trials 52

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. For more on FDORA’s other provisions, see HPM’s complete summary here ). FDORA § 3209(a)(2).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays Clinical Trials 64

DrugBank

FEBRUARY 12, 2025

Key techniques include high-throughput screening (HTS), cell-based assays, and animal models. Cell-Based Assays In vitro, drug efficacy, and toxicity testing in cell cultures provide valuable preclinical data. The drug's unexpected side effects during clinical trials led to its repurposing.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52